| Next month » |
Agilent Technologies has launched a software package to help drug companies keep a close eye on the quality of chemical compounds. The firm says the product is the first of its kind, allowing a more than seven-fold increase in the number analytical instruments that can be monitored from a single PC.
Honeywell has signed a deal with Korea's SK Chemicals that will expand its production of high-purity solvents in Asia.
Filtration specialist Millipore has reported strong growth in sales in the fourth quarter of 2003, suggesting that the fortunes of the biopharmaceutical industry - Millipore's primary customer - may be on the up.
Eksigent Technologies is launching a new high-pressure liquid chromatography system in March that can increase throughput compared to rival HPLC systems as much as six-fold.
Australia's Gradipore has been boosted by news that its Gradiflow separation technology has been scaled up to produce commercial quantities of an antibody from source plasma.
UK-headquartered NextGen Sciences has formed an alliance with Germany's Protagen aimed at developing 'biochips' that can contain thousands of functional proteins for use in drug discovery.
Agilent Technologies has launched a simplified method for detecting sulphonamide antibiotics in pork. The company claims that the method reliably measures sulphonamides at lower than half the European Union and Canadian regulatory limits of 100 parts per billion (ppb) in meat.
Amersham Biosciences has responded to competition in the marketplace for purifying tagged proteins with the launch of Ni Sepharose, a new affinity chromatography medium.
The UK government has unveiled plans to modernise its patent rules and bring them into line with the revised European Patent Convention.
Affymetrix and liquid-handling specialist Caliper Technologies - now renamed Caliper Life Sciences - are collaborating on ways of automating genomics research carried out using microarrays.
French-based technology group BioMérieux is developing gene chips that can be used to ensure food safety and enhance traceability. The company, which is set to launch the product next month, is keeping tight-lipped about the product, but there is speculation that the concept could represent a breakthrough in food production.
Food technology firm Oxoid has expanded its range of microbiological tests for the food industry to include two new diagnostic reagents kits - one for Salmonella and another for Listeria species. The company claims that both test kits are easy to use.
Labcaire of the UK is upgrading its entire range of laboratory safety cabinets by coating them with an antimicrobial treatment designed to minimise the risk of cross-contamination.
Colony counting and picking are well-recognised as one of the most boring, repetitive and error-prone jobs in the lab, and there has been a strong desire to automate the process.
Qiagen of the Netherlands has started shipping a set of RNA interference (RNAi) reagents that correspond to the 5,000 or so genes in the human genome thought most likely to be viable targets for drug discovery.
The pharmaceutical industry must cut the time its drugs linger in development and terminate less promising projects earlier if it is to improve the efficiency and productivity of its R&D programmes.
Senior executives at LGC, a UK-headquartered provider of pharmaceutical reference materials and analytical and diagnostic services, are gearing up for a secondary buyout that will help it to accelerate its expansion into international markets.
Indian companies may be making great strides in capturing international market shares for bulk pharmaceutical ingredients and generic drugs, but to date they have not made a great impression on the laboratory tool market.
In 2003, Freeman Technology launched its new-generation FT4 rheometer in Europe for testing the flow properties of powders, an important measurement in the pharmaceutical and chemical industries where most processes involve the extensive use of powdered compounds.
New tests that slice off the time taken to identify dangerous strains of the harmful bacteria Escherichia coli are the focus of new research from US government scientists.
Life sciences technology company Invitrogen has entered into a definitive agreement to acquire fellow US firm BioReliance, which specialises in the testing and manufacture of biologic drugs.
| Next month » |